sublingual tirzepatide oral drops (13mg) Tirzepatide Oral Sublingual Tablets in

It should not be shared with others

Nausea (most common, typically dose-dependent and transient) Diarrhea or constipation during dose escalation Vomiting, especially when starting or increasing dose Reduced appetite and early satiety Injection site reactions (redness, bruising) Fatigue, particularly in early weeks Rare: Pancreatitis discontinue immediately with severe abdominal pain Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history) AOD-9604 is a modified C-terminal fragment (residues 176191, Tyr-hGH177-191) of human growth hormone, studied for lipolytic and anti-obesity properties

127 Rajamand Ekberg, N

FDA-approved weight management medications beyond GLP-1 agonists include: Phentermine-topiramate (Qsymia): Combination sympathomimetic and anticonvulsant showing 8-10% weight loss in clinical trials